We confirmed this issue (Fig 1) and we therefore selected GBM cellular models as experimental systems to test the hypothesis that other signaling pathways often deregulated in GBM may contribute to increase NRF2 expression levels. The gene discussed is NFE2L2; the disease is glioblastoma.